leisure time -WSS

leisure time

author：knowledge 2025-09-29 21:15:03 - browse：7287

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Medicare must police algorithms in Medicare Advantage, Dems say

hotspot

WSS

Lung cancer screening guidelines updated for cigarette smokers

Gene therapy’s promise and the high cost of hope

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Explaining an after

Coloradans with cystic fibrosis could lose access to Trikafta

Readout LOUD podcast: ESMO highlights & Roivant's big deal

leisure time

leisure time

focus

ChatGPT in medicine: STAT answers readers' burning questions

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Peter Hotez and the public health issue of online harassment

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Duchenne breakthrough therapy leaves behind pioneering families

Brain injuries and the importance of a second opinion

Trump demands the U.S. pay no more for drugs than other countries … again

Top private equity targets in 2023: cardiology, clinical trials, lasers

Medicare details structure of new drug price negotiation program

Brain injuries and the importance of a second opinion

explore

Bernie brings in new pharma CEOs to talk drug prices

Key Senate panel to consider PBM, drug pricing reform package

How neuroscience research could help beat back brain cancer

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Sarepta Duchenne therapy fails to meet primary endpoint in trial

What is microchimerism and how does it affect maternal health?

leisure time

leisure time

hotspot

focus